About Alimera Sciences
Alimera Sciences is a company based in Alpharetta (United States) founded in 2003 was acquired by ANI Pharmaceuticals in July 2024. It operates as a Reseller / Distribution. Alimera Sciences has raised $66.8 million across 9 funding rounds from investors including ANI Pharmaceuticals, SLR Investment Corp and Lincoln Park Capital. The company has 79 employees as of December 31, 2022. Alimera Sciences offers products and services including Ophthalmic Products. Alimera Sciences operates in a competitive market with competitors including Kriya Therapeutics, Annexon, Aldeyra, Nicox and Gyroscope, among others.
- Headquarter Alpharetta, United States
- Employees 79 as on 31 Dec, 2022
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Alimera Sciences Europe Ltd
-
Annual Revenue
$80.75 M (USD)49as on Dec 31, 2023
-
Net Profit
-$20.13 M (USD)-11as on Dec 31, 2023
-
EBITDA
$6.82 M (USD)176as on Dec 31, 2023
-
Total Equity Funding
$66.8 M (USD)
in 9 rounds
-
Latest Funding Round
$81 M (USD), Post-IPO
May 31, 2023
-
Investors
ANI Pharmaceuticals
& 7 more
-
Employee Count
79
as on Dec 31, 2022
-
Acquired by
ANI Pharmaceuticals
(Jul 17, 2024)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Alimera Sciences
Alimera Sciences offers a comprehensive portfolio of products and services, including Ophthalmic Products.
Products for eye conditions are developed and distributed.
People of Alimera Sciences
Unlock access to complete
Funding Insights of Alimera Sciences
Alimera Sciences has successfully raised a total of $66.8M across 9 strategic funding rounds. The most recent funding activity was a Post-IPO round of $81 million completed in May 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Alimera Sciences
Alimera Sciences has secured backing from 8 investors, including venture fund investors. Prominent investors backing the company include ANI Pharmaceuticals, SLR Investment Corp and Lincoln Park Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Private equity investments are directed toward North American opportunities.
|
Locked | Locked | Locked | |
|
Debt and equity investments are offered by the firm.
|
Locked | Locked | Locked | |
|
US focused venture capital firm
|
Locked | Locked | Locked |
Investor details for Alimera Sciences
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Alimera Sciences
Investment portfolio details for Alimera Sciences
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Alimera Sciences
Detailed financials for Alimera Sciences
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Alimera Sciences Comparisons
Peer comparison for Alimera Sciences
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Alimera Sciences
Alimera Sciences operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Kriya Therapeutics, Annexon, Aldeyra, Nicox and Gyroscope, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of therapeutic solutions for the treatment of diabetes
|
|
| Locked | Locked | Locked |
Developer of antibodies to treat complement-mediated neurodegenerative diseases
|
|
| Locked | Locked | Locked |
Drug candidates for immune-mediated diseases are developed by Aldeyra.
|
|
| Locked | Locked | Locked |
Nitric oxide-based therapeutics for glaucoma and eye conditions are developed.
|
|
| Locked | Locked | Locked |
Mobile SDK developed for app engagement and monetization strategies.
|
|
| Locked | Locked | Locked |
Gene therapies for ocular and neurodegenerative diseases are developed.
|
Detailed competitors of Alimera Sciences
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Alimera Sciences
Complete news archive for Alimera Sciences
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Alimera Sciences
Alimera Sciences was founded in 2003 and raised its 1st funding round 2 years after it was founded.
Alimera Sciences is headquartered in Alpharetta, United States. It is registered at Alpharetta, Georgia, United States.
Alimera Sciences is a funded company, having raised a total of $66.8M across 9 funding rounds to date.
As of Dec 31, 2022, the latest employee count at Alimera Sciences is 79.
Annual revenue of Alimera Sciences is $80.75M as on Dec 31, 2023.
Alimera Sciences is involved in the distribution of ophthalmic pharmaceutical products across Europe, the Middle East, and Africa. The company collaborates with a network of distribution partners to provide solutions for eye-related conditions. Operations are focused on ensuring access to specialized treatments in various countries within these regions.
Alimera Sciences offers Ophthalmic Products.
Alimera Sciences has 8 investors. Key investors include ANI Pharmaceuticals, SLR Investment Corp, Lincoln Park Capital, Polaris Partners, and Intersouth Partners.